FindTrial
Sign In

Comparing the duration of action of drug levobupivacaine with bupivacaine in females under going gynecological surgeries done under spinal anaesthesia

Comparison of Hyperbaric levobupivacaine with hyperbaric bupivacaine in gynaecological surgeries performed under spinal anaesthesia-Randomized control Trial.

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2023/07/055380
Enrollment
70
Registered
2023-07-20
Start date
Unknown
Completion date
Unknown
Last updated
2023-07-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N71- Inflammatory disease of uterus, except cervix

Interventions

Intervention1: Hyperbaric Bupivacaine: Group 2 (HB) Will receive 0.5% of Hyperbaric bupivacaine 3.5ml Control Intervention1: Hyperbaric levobupivacaine: Group 1 (HL) Will receive 0.5% of Hyperbaric Le

Sponsors

Priyadharshini.P
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1.Women belongs to ASA I and ASA II posted for Gynaecological surgeries.

Exclusion criteria

Exclusion criteria: 1.Women with ASA III and ASA IV. 2.Hypersensitivity to local anaesthetic agent. 3.Backache,Scoliosis or having a history of back surgery. 4.Infection on the injection site. 5.Clotting and hemorrhagic disorders. 6.Refusal to Spinal anaesthesia. 7.Height Shorter than 150cms or longer than 180cms.

Design outcomes

Primary

MeasureTime frame
To compare the level of motor and sensory blockadeTimepoint: 1 hour,2 hour,4 hour,6 hour, 12 hour,18 hour—

Secondary

MeasureTime frame
Duration of postop analgesia. To compare the intraoperative hemodynamic changes. Incidence of side effects like nausea,vomiting and pruritisTimepoint: 1 hour,2 hour,4 hour,6 hour,12 hour,18 hour—

Countries

India

Contacts

Public ContactDrVijay narayanan

Shrisathya sai medical college and research institute

dr.vijay@live.in9444877188

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026